Developing Tomorrow’s Treatments
Anaveon is well positioned to be a leader in the field of engineered
Anaveon’s mission is to transform cytokines into life-saving treatments. The Company was founded in 2017 by experts in cutting-edge immunology, who wanted to design and develop patient treatments that benefit society.
This remains our vision today. Anaveon is a biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. The team has the skills to make this vision a reality: we are committed to transforming immunological insights into life-saving therapies.
Others share our vision, and investors have backed Anaveon with funding of more than 146 million CHF (€140 million).
Our dedicated team of drug developers is already 15 strong and growing. Anaveon’s expert scientists have decades of experience in drug development. Their expertise and drive to deliver tangible results are what sets our company apart.
Since 2017, Anaveon has grown in size and strength.
The first drug we are testing in clinical trials is
ANV419 – a selective
Company Information Pack
Discover Anaveon®
Read about Anaveon’s work towards our mission to transform cytokines into life-saving treatments. In this downloadable info package, you can find out more about the company, our team of dedicated experts, the drugs we are assessing in clinical trials, and the programs we have in the pipeline.
Want to know more?
To ask us a question, or find out about collaboration opportunities, email us at contact@anaveon.com.
Anaveon®’s pipeline based on engineered cytokines
Anaveon is exploiting the power of cytokines to orchestrate immune responses through safe and effective treatments for a variety of serious diseases. Our pipeline reflects this: we are developing
a unique no-alpha
Discovery
Lead Optimization
Preclinical Development
Phase I/II
Phase1
Lead Optimization
Discovery
Therapeutic Areas
The programs in Anaveon’s pipeline have potential across a range of therapeutic areas.
Solid
tumors
Cytokine immunotherapies could be used to treat solid tumors, including melanoma, renal cell cancer and bladder cancer.
Hematological
malignancies
Cancers of the blood, bone marrow and lymph nodes are potential targets, including leukemia, lymphoma and myeloma.
Combination
therapy
The programs in Anaveon’s pipeline could be used in combination with checkpoint inhibitors, innate immunity agonists, targeted agents or depleting antibodies.
Combination with
cell therapies
In combination with cutting-edge cell therapies, Anaveon’s programs could offer new benefits for cancer patients.
Quick Facts
- ANV419 is a fusion protein of
IL-2 with ananti-IL-2 antibody - In vitro and in vivo, ANV419 selectively signals through the IL-2Rβ/γ and promotes the expansion of both NK and CD8+ T cells but not Tregs
- ANV419 is currently in first human studies to determine the optimal dose for safety and efficacy
- Development in multiple cancer indications are initiating in 2022
Competitive Advantage
ANV419 has already displayed exceptional safety in early clinical studies and non-human primates. It is selective by design: ANV419 only promotes the function of CD8+ T cells and NK cells as immune effector cells while sparing regulatory T cells. Therefore, it is a potential treatment for a range of cancer types.
Latest Publications
ANV419 is a novel CD122 selective IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T cell and NK cell stimulatory function in vitro and in vivo
SITC Annual Meeting. 2020 Nov 9-14
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human Interleukin-2
Sci Transl Med. 2016 Nov 30;8(367):367ra166.
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
Immunity. 2015 May 19;42(5):815-25
Start your journey with Anaveon® today
News
11
April
2022
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
As of the March 11, 2022 data cut-off date, 16 patients in 7 dosing cohorts with different types of progressing cancer received ANV419 every 14 days. ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment. No patients experienced a Grade 3 or worse drug related AE and no patients have withdrawn from study due to AEs. No dose limiting toxicities have been observed.
09
March
2022
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022
Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisana, April 8 to April 13, 2022.
16
December
2021
Anaveon to raise CHF 110 million in oversubscribed Series B financing
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.
12
November
2021
Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held from Wednesday, November 10, 2021 to Sunday, November 14, 2021.
24
June
2021